Compare EPR Properties (EPR) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

EPR Properties (EPR) trades at $54.80, down 1.1% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The REIT shows strong profitability with a 91.41% gross margin and 37.66% net income margin, though net income dipped slightly in 2026. Recent news highlights its 6.5% dividend yield and focus on diversification beyond theaters into experiential properties, with Q3 2026 earnings due October 29, 2026.

The outlook is mixed: analyst consensus is a Buy with a $65.50 price target, implying ~20% upside, supported by a high yield and undervalued P/FFO. Risks include exposure to leisure and entertainment tenants, rising interest rates impacting financing costs, and the Q1 2026 earnings miss. Cash flow trends show a net outflow in 2026, warranting monitoring of dividend coverage.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.